CN101415420B - 用于治疗癌症的治疗剂的组合 - Google Patents

用于治疗癌症的治疗剂的组合 Download PDF

Info

Publication number
CN101415420B
CN101415420B CN2007800122350A CN200780012235A CN101415420B CN 101415420 B CN101415420 B CN 101415420B CN 2007800122350 A CN2007800122350 A CN 2007800122350A CN 200780012235 A CN200780012235 A CN 200780012235A CN 101415420 B CN101415420 B CN 101415420B
Authority
CN
China
Prior art keywords
inhibitors
inhibitor
kinase
compounds
tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800122350A
Other languages
English (en)
Chinese (zh)
Other versions
CN101415420A (zh
Inventor
G·伯克
R·R·林纳兹
P·M·J·麦克希伊
R·W·弗塞斯
M·瓦特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101415420A publication Critical patent/CN101415420A/zh
Application granted granted Critical
Publication of CN101415420B publication Critical patent/CN101415420B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2007800122350A 2006-04-05 2007-04-04 用于治疗癌症的治疗剂的组合 Expired - Fee Related CN101415420B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78940206P 2006-04-05 2006-04-05
US60/789,402 2006-04-05
PCT/US2007/065908 WO2007121088A2 (en) 2006-04-05 2007-04-04 Combinations of therapeutic agents for treating cancer

Publications (2)

Publication Number Publication Date
CN101415420A CN101415420A (zh) 2009-04-22
CN101415420B true CN101415420B (zh) 2012-09-05

Family

ID=38606595

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800122350A Expired - Fee Related CN101415420B (zh) 2006-04-05 2007-04-04 用于治疗癌症的治疗剂的组合

Country Status (11)

Country Link
US (2) US20100173934A1 (enExample)
EP (1) EP2004184A2 (enExample)
JP (1) JP2009536153A (enExample)
KR (1) KR20090005310A (enExample)
CN (1) CN101415420B (enExample)
AU (1) AU2007238307B2 (enExample)
BR (1) BRPI0709744A2 (enExample)
CA (1) CA2645278A1 (enExample)
MX (1) MX2008012717A (enExample)
RU (1) RU2449788C2 (enExample)
WO (1) WO2007121088A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2009114A1 (en) * 2007-06-29 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
KR101309578B1 (ko) 2011-05-06 2013-09-17 연세대학교 산학협력단 시스테인 프로테아제 선택성을 갖는 다이타이로신 화합물 및 이를 이용한 시스테인 프로테아제의 검출방법
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
KR101388776B1 (ko) 2012-07-31 2014-04-23 성균관대학교산학협력단 2，3―비스［（2―하이드록시에틸）티오］―1，4―나프토퀴논을 포함하는 항염증용 조성물
EP3131550B1 (en) * 2014-04-16 2021-05-26 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy with a histone deacetylase inhibitor
EP3204776B1 (en) * 2014-10-10 2019-09-04 F.Hoffmann-La Roche Ag Methods for personalizing patient cancer therapy with an mdm2 antagonist
CN106146509A (zh) * 2015-03-24 2016-11-23 重庆大学 一种抑制乳腺癌增殖的化合物及其应用
US11890292B2 (en) 2017-02-27 2024-02-06 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
CN108864057B (zh) * 2017-05-16 2020-03-31 山东大学 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療
WO2019071229A1 (en) * 2017-10-06 2019-04-11 Research Cancer Institute Of America COMPOSITIONS, METHODS, SYSTEMS AND / OR KITS FOR PREVENTING AND / OR TREATING NEOPLASMS
US12213958B2 (en) 2017-11-17 2025-02-04 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
CN113181117B (zh) * 2021-03-22 2022-08-26 沈阳药科大学 一种紫草素和蒽环类化疗药共载脂质体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
DE60031268T2 (de) * 1999-04-14 2007-05-24 Dana-Farber Cancer Institute, Inc., Boston Verfahren und zusammansetzung zur behandlung von krebs
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
WO2003039536A1 (en) * 2001-11-07 2003-05-15 Yale University Enhancement of taxane-based chemotherapy by a cdk1 antagonist
US6900331B2 (en) * 2002-03-01 2005-05-31 University Of Notre Dame Derivatives of epothilone B and D and synthesis thereof
RU2379032C9 (ru) * 2002-06-10 2010-03-27 Новартис Аг Комбинации, включающие эпотилоны, и их фармацевтическое применение
AU2003275068B2 (en) * 2002-09-23 2009-09-17 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and X-Ray crystal structures of epothilone B

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HANKE J H et al..Discovery of a nover, potent, and SRC Family-selective tyrosine kinase inhibitor.《JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM》.1996,第271卷(第2期),695-701. *

Also Published As

Publication number Publication date
EP2004184A2 (en) 2008-12-24
CN101415420A (zh) 2009-04-22
WO2007121088A2 (en) 2007-10-25
MX2008012717A (es) 2008-10-14
RU2449788C2 (ru) 2012-05-10
KR20090005310A (ko) 2009-01-13
RU2008143553A (ru) 2010-05-10
AU2007238307A1 (en) 2007-10-25
AU2007238307B2 (en) 2011-06-09
BRPI0709744A2 (pt) 2011-07-26
US20100173934A1 (en) 2010-07-08
JP2009536153A (ja) 2009-10-08
CA2645278A1 (en) 2007-10-25
US20110257206A1 (en) 2011-10-20
WO2007121088A3 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
CN101415420B (zh) 用于治疗癌症的治疗剂的组合
CN101415409B (zh) 用于治疗癌症的治疗剂的组合
CN101415424B (zh) 用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
CN101626758A (zh) 用于治疗癌症的lbh589和其他治疗剂的组合
US20090099103A1 (en) Combinations of therapeutic agents for treating cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120905

Termination date: 20130404